US Edition
Published • loading... • Updated
Danaher to Buy Masimo in $9.9 Billion Deal in Diagnostics Push
Danaher will pay a 38.3% premium in cash for Masimo, aiming to boost diagnostics with expected $0.15 to $0.20 earnings accretion in the first full year.
- Danaher Corporation said today it agreed to acquire Masimo Corporation for $180 per share in cash, valuing the deal at about $9.9 billion, a 38.3% premium to the last close.
- By acquiring Masimo, Danaher aims to bulk up its diagnostics business and expand into patient-monitoring products such as oximeters, complementing Radiometer blood analyzers and strengthening its diagnostics franchise.
- On valuation metrics, the deal represents about 18x 2027 estimated EBITDA or 15x including expected annual synergies, with Masimo generating EBITDA of over $530 million in 2027.
- Masimo shares jumped 34.3% to $174.89 in premarket trading while Danaher stock fell, and the companies expect closing by the second half of 2026 with Citi and Kirkland & Ellis LLP advising.
- The acquisition is Danaher's biggest since its $5.7 billion Abcam acquisition in 2023 and follows Masimo's Sound United sale for $350 million and a proxy contest led by activist Politan removing Joe Kiani.
Insights by Ground AI
20 Articles
20 Articles
Danaher to Acquire Masimo in $9.9 Billion Deal to Expand Diagnostics Market
In a move designed to strengthen its global patient diagnostics market, Danaher Corporation, a Washington-based science and technology firm, plans to merge operations with Masimo Corporation, a leading specialty diagnostics company headquartered in Irvine, California. In its Feb. 17 announcement, Danaher said it will acquire all of Masimo’s outstanding shares of common stock for $180 per share in cash, carrying a total value of nearly $9.9 billi…
·New York, United States
Read Full Article
Coverage Details
Total News Sources20
Leaning Left2Leaning Right3Center7Last UpdatedBias Distribution58% Center
Bias Distribution
- 58% of the sources are Center
58% Center
L 17%
C 58%
R 25%
Factuality
To view factuality data please Upgrade to Premium
